

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Takahide KOHRO et al.**

Application Number: **Not yet assigned**  
(**§371 of international application No. PCT/JP2005/003008**)

Filed: **August 24, 2006**

For: **NUCLEAR TRANSFER PROMOTER FOR Cdc42  
PROTEIN AND METHOD OF SCREENING THE  
SAME**

Attorney Docket Number: **032217A**  
Customer Number: **38834**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

August 24, 2006

Sir:

In compliance with 37 C.F.R. §1.56, Applicants direct the attention of the Patent and Trademark Office to the documents listed on the attached PTO/SB/08. A copy of each non- U.S. document is enclosed herewith as well as an International Search Report mailed June 7, 2005.

If there are any fees due in connection with the filing of this paper, please charge Deposit Account No. 50-2866.

Respectfully submitted,

**WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP**



Sadao Kinashi

Attorney for Applicants  
Registration No. 48,075  
Telephone: (202) 822-1100  
Facsimile: (202) 822-1111

SK/mc

Enclosure: PTO/SB/08, Documents (10) & Int'l Search Report

10/590492

IAP12 Rec'd PCT/PTO 24 AUG 2006

Combined Form PTO/SB/08A&B				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	Not yet assigned
				Confirmation Number	
				Filing Date	August 24, 2006
				First Named Inventor	Takahide KOHRO et al.
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	032217A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>3</sup> (if known)		
	US				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>			
	-					

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.					Translation <sup>4</sup>
/A.P./	1	KATSUHIKO MASAMURA et al., "Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family", <i>Arterioscler. Thromb. Vasc. Biol.</i> , Vol. 23, No. 3, pp. 512-517 (2003)					
/A.P./	2	SHIGERU MORIKAWA et al., "The Effect of Statins on mRNA Levels of Genes Related to Inflammation, Coagulation, and Vascular Constriction in HUVEC", <i>Human Umbilical Vein Endothelial Cells, J.Atheroscler.Thromb.</i> , Vol. 9, No. 4, pp. 178-183 (2002)					
/A.P./	3	MARIE F. MCCARTY et al., "Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway", <i>Med. Hypotheses</i> , Vol. 60, No. 5, pp. 634-639 (2003)					
/A.P./	4	R.P. BRANDES et al., "Withdrawal of Cerivastatin Induces Monocyte Chemoattractant Protein 1 and Tissue Factor Expression in Cultured Vascular Smooth Muscle Cells", <i>Arterioscler.Thromb.Vasc.Biol.</i> , Vol. 23, No. 10, pp. 1794-1800 (2003)					
/A.P./	5	ANDREAS H. WAGNER et al., "Improvement of Nitric Oxide-Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion Formation", <i>Arterioscler.Thromb.Vasc.Biol.</i> , Vol. 20, No. 1, pp. 61-69 (2000)					
/A.P./	6	MASAO TAKEMOTO et al., "Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors", <i>Arterioscler.Thromb.Vasc.Biol.</i> , Vol. 21, No. 11, pp. 1712-1719 (2001)					
/A.P./	7	MASATO ETO et al., "Modulation of Coagulation and Fibrinolytic Pathways by Statins", <i>Endothelium</i> , Vol. 10, No. 1, pp. 35-41 (2003)					
/A.P./	8	MICHAL MYSLIWIEC et al., "Statin therapy – more than lipid – lowering effect", <i>Advances in Clinical and Experimental Science</i> , Vol. 12, No. 2, pp. 185-190 (2003)					
/A.P./	9	CARMINE VECCHIONE et al., "Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice", <i>Circulation Research</i> , Vol. 91, No. 2, pp. 173-179 (2002)					
/A.P./	10	MARINA CAMERA et al., "Cholesterol-induced Thrombogenicity of the Vessel Wall: Inhibitory Effect of Fluvastatin", <i>Thrombosis and Haemostasis</i> , Vol. 87, No. 4, pp. 748-755 (2002)					
	11	International Search Report mailed June 7, 2005 of International Application PCT/JP2005/002008					
Examiner Signature	/Anna Pagonakis/			Date Considered	08/26/2008		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.